ES249137A1 - Reagent and method for determining the coagulability of blood - Google Patents
Reagent and method for determining the coagulability of bloodInfo
- Publication number
- ES249137A1 ES249137A1 ES0249137A ES249137A ES249137A1 ES 249137 A1 ES249137 A1 ES 249137A1 ES 0249137 A ES0249137 A ES 0249137A ES 249137 A ES249137 A ES 249137A ES 249137 A1 ES249137 A1 ES 249137A1
- Authority
- ES
- Spain
- Prior art keywords
- cephalin
- factor
- plasma
- reagent
- bovine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 5
- 210000004369 blood Anatomy 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 210000002381 plasma Anatomy 0.000 abstract 8
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 abstract 6
- 241000283690 Bos taurus Species 0.000 abstract 6
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 abstract 4
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 4
- 108010023321 Factor VII Proteins 0.000 abstract 4
- 108010094028 Prothrombin Proteins 0.000 abstract 4
- 102100027378 Prothrombin Human genes 0.000 abstract 4
- 108010000499 Thromboplastin Proteins 0.000 abstract 4
- 102000002262 Thromboplastin Human genes 0.000 abstract 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 4
- 229940039716 prothrombin Drugs 0.000 abstract 4
- 238000012360 testing method Methods 0.000 abstract 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 2
- 102100029117 Coagulation factor X Human genes 0.000 abstract 2
- 102100030556 Coagulation factor XII Human genes 0.000 abstract 2
- 241000283073 Equus caballus Species 0.000 abstract 2
- 108010014173 Factor X Proteins 0.000 abstract 2
- 108010080865 Factor XII Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 2
- 241000282898 Sus scrofa Species 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 2
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 2
- 239000001110 calcium chloride Substances 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000015271 coagulation Effects 0.000 abstract 2
- 238000005345 coagulation Methods 0.000 abstract 2
- 238000000502 dialysis Methods 0.000 abstract 2
- 229940067606 lecithin Drugs 0.000 abstract 2
- 235000010445 lecithin Nutrition 0.000 abstract 2
- 239000000787 lecithin Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000011575 calcium Substances 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 229910001427 strontium ion Inorganic materials 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A reagent for testing the coagulability of blood during treatment with anticoagulent agents comprises thromboplastin in optimal concentration having a Quick's thromboplastin time of at least 35 seconds with normal human plasma in admixture with cephalin or a cephalin substitute, e.g. lecithin. Bovine plasma from which prothrombin, Stuart-factor, proconvertin and antihemophilia-B-factor have been removed and which contains high concentrations of antihemophilia-A and -C-factors, Hagemanfactor, proaccelarin and proconvertin, and calcium chloride may also be present, the latter in an amount sufficient to give the optimal concentration of Ca\sR\sR ions for coagulation after the addition of test plasmas. The reagent may be freeze-dried to give a stable, solid preparation which may be reconstituted before use. The prothrombin may be prepared by known procedures from animal (e.g. bovine, horse, swine) brain and the cephalin from human brain. The bovine plasma may be obtained by the treatment thereof with barium sulphate followed by dialysis to remove oxalate and the carbonic acid/bicarbonate buffer system and adjustment of the pH to from 6-8.ALSO:A reagent for testing the coagulability of blood during treatment with anticoagulent agents comprises thromboplastin in optional concentration having a Quick's thromboplastin time of at least 35 seconds with normal human plasma in admixture with cephalin or a cephalin substitute e.g. lecithin. Bovine plasma from which prothrombin, Stuart-factor, proconvertin and antihaemophilia-b -factor have been removed and which contains high concentrations of antihaemophilia-A and -C-factors, Hageman-factor, proaccelarin and proconvertin, and calcium chloride may also be present, the latter in amounts sufficient to give the optimal concentration of CA++ ions for coagulation after the addition of test plasma. The reagent may be freeze-dried to give a stable, solid preparation which may be reconstituted before use. The prothrombin may be prepared by known methods from animal (e.g. bovine, horse, swine) brain and the cephalin from human brain. The bovine plasma may be obtained by the treatment thereof with barium sulphate followed by dialysis to remove oxalate and the carbonic acid/bicarbonate buffer system and adjustment of the pH to from 6 to 8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO12810458 | 1958-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES249137A1 true ES249137A1 (en) | 1959-11-16 |
Family
ID=19908436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES0249137A Expired ES249137A1 (en) | 1958-05-16 | 1959-05-02 | Reagent and method for determining the coagulability of blood |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3179567A (en) |
| CH (1) | CH408283A (en) |
| DE (1) | DE1189763B (en) |
| ES (1) | ES249137A1 (en) |
| FR (1) | FR1223856A (en) |
| GB (1) | GB917012A (en) |
| NL (2) | NL238873A (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3293134A (en) * | 1961-09-08 | 1966-12-20 | Warner Lambert Pharmaceutical | Diagnostic reagent composition for determining blood coagulation factors and method of use |
| US3395210A (en) * | 1964-02-07 | 1968-07-30 | Warner Lambert Pharmaceutical | Lyophilized diagnostic reagent for the determination of blood coagulation factors |
| US3486981A (en) * | 1965-03-15 | 1969-12-30 | Roy E Speck | Substances relating to testing of blood-coagulation |
| US3228841A (en) * | 1965-06-10 | 1966-01-11 | Warner Lambert Pharmaceutical | Diagnostic reagent composition for determining blood coagulation factors and method of use |
| US3880714A (en) * | 1973-07-18 | 1975-04-29 | Warner Lambert Co | Diagnostic reagent |
| US3947378A (en) * | 1974-12-23 | 1976-03-30 | Warner-Lambert Company | Adsorbed plasma |
| US4002739A (en) * | 1975-02-18 | 1977-01-11 | Warner-Lambert Company | Soluble collagen |
| US4038147A (en) * | 1976-06-15 | 1977-07-26 | Becton, Dickinson And Company | Method for detecting endotoxins |
| DE2915310A1 (en) * | 1979-04-14 | 1980-10-30 | Behringwerke Ag | NEW PARTIAL THROMBOPLASTINE AND THEIR USE |
| DE3150596A1 (en) * | 1981-12-21 | 1983-06-30 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD FOR PRODUCING TISSUE HROMBOPLASTIN |
| DE3407280A1 (en) * | 1984-02-28 | 1985-09-19 | Gödecke AG, 1000 Berlin | TEST SET FOR DETERMINING THE ACTIVATED PARTIAL THROMBOPLASTIN TIME (PTT) WITH INCREASED HEPARINE SENSITIVITY |
| DE3413311A1 (en) * | 1984-04-09 | 1985-10-17 | Behringwerke Ag, 3550 Marburg | REAGENT FOR DETERMINING THROMBOPLASTIN TIME |
| US4946775A (en) * | 1985-09-05 | 1990-08-07 | Yin E Thye | Composition, kit and method for assaying heparin and a method for making the composition |
| US4948724A (en) * | 1985-09-05 | 1990-08-14 | Yin E Thye | Composition, kit and method for assaying heparin and a method for making the composition |
| US4851336A (en) * | 1985-09-05 | 1989-07-25 | Yin E Thye | Composition, kit, and method for assaying heparinano a method for making the composition |
| US4755461A (en) * | 1986-04-17 | 1988-07-05 | Bio/Data Corporation | Tableted blood plasma microconcentrated thromboplastin coagulation reagent |
| AU744287B2 (en) * | 1990-11-13 | 2002-02-21 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US5314695A (en) * | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US6203816B1 (en) * | 1990-11-13 | 2001-03-20 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US6248353B1 (en) | 1999-12-10 | 2001-06-19 | Dade Behring Inc. | Reconstitution of purified membrane proteins into preformed liposomes |
| US6596543B2 (en) | 2001-03-22 | 2003-07-22 | Dade Behring Inc. | Use of liposomes of defined composition and size for the preparation of prothrombin time reagents |
| IS2809B (en) * | 2011-03-08 | 2012-10-15 | Haskoli Islands | Method for monitoring anticoagulant therapy |
| CN111295094A (en) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | Freeze-drying container and method for using freeze-drying container |
| WO2020242552A1 (en) | 2019-03-14 | 2020-12-03 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| CN112481355B (en) * | 2020-11-16 | 2023-05-30 | 武汉市长立生物技术有限责任公司 | Liquid prothrombin time determination kit and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2687980A (en) * | 1948-09-15 | 1954-08-31 | Ernest W Blanchard | Thromboplastin product and method for preparing same |
| US2847350A (en) * | 1954-05-27 | 1958-08-12 | Ortho Pharma Corp | Preparation of highly active thromboplastin |
-
0
- NL NL123584D patent/NL123584C/xx active
- NL NL238873D patent/NL238873A/xx unknown
-
1959
- 1959-03-31 GB GB10940/59A patent/GB917012A/en not_active Expired
- 1959-04-30 DE DEO6747A patent/DE1189763B/en active Pending
- 1959-05-02 ES ES0249137A patent/ES249137A1/en not_active Expired
- 1959-05-04 CH CH7286559A patent/CH408283A/en unknown
- 1959-05-05 FR FR794205A patent/FR1223856A/en not_active Expired
- 1959-05-12 US US812682A patent/US3179567A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR1223856A (en) | 1960-06-21 |
| GB917012A (en) | 1963-01-30 |
| NL123584C (en) | |
| NL238873A (en) | |
| CH408283A (en) | 1966-02-28 |
| DE1189763B (en) | 1965-03-25 |
| US3179567A (en) | 1965-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES249137A1 (en) | Reagent and method for determining the coagulability of blood | |
| Schousboe et al. | Uptake and metabolism of glutamate in astrocytes cultured from dissociated mouse brain hemispheres | |
| Seligson et al. | The measurement of ammonia in whole blood, erythrocytes, and plasma | |
| JP3055933B2 (en) | Improved stable coagulation control | |
| Owen et al. | Prothrombin conversion factor of dicumarol plasma. | |
| Stefanini | Mechanism of blood coagulation in normal and pathologic conditions | |
| Hawkins et al. | Studies on cholinesterase. 6. The selective inhibition of true cholinesterase in vivo | |
| JP3348228B2 (en) | Improved extraction method for producing thromboplastin reagent | |
| JPS56106594A (en) | Stabilizing method of plasminogen | |
| Booth | Carbonic anhydrase activity inside corpuscles. Enzyme-substrate accessibility factors | |
| CA3083551C (en) | Prothrombin time reagent comprising an iron chelator | |
| McIlwain et al. | Induced loss in cerebral tissues of respiratory response to electrical impulses, and its partial restoration by additional substrates | |
| Spaet et al. | Inactivation of thromboplastin in human blood | |
| DOERR et al. | New evidence for intrinsic blood coagulation in chickens | |
| Gotterer et al. | Some factors which influence vesiculase action | |
| Wadhwa et al. | The absorption of calcium ions from the ovine reticulo-rumen | |
| Mellanby et al. | Calcium and blood coagulation | |
| McClaughry et al. | Nature of an accelerator of prothrombin activation arising during storage of purified prothrombin. | |
| Kinlough-Rathbone et al. | Divalent cations and the release reaction of pig platelets | |
| Spinka et al. | Antisera for Organ-Proteins | |
| GB1003748A (en) | Diagnostic compositions for the determination of blood coagulant factor levels | |
| Sjølin | The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease | |
| JPS63235867A (en) | Preparation of viii-c factor deficiency plasma and deficiency plasma obtained through said method | |
| GB906860A (en) | Improvements relating to blood coagulation test reagents | |
| Mann et al. | Relation of complement to blood coagulation |